Ipamorelin vs CJC-1295: Mechanism, Dosing, and Why Most Protocols Combine Them

Ipamorelin and CJC-1295 are two peptides that keep getting discussed together for a specific reason: they activate growth hormone release through completely independent receptors. That's why practically every protocol pairs them rather than choosing between them. This article covers what each does alone, what the combination actually adds mechanistically, and the DAC vs non-DAC distinction that trips most first-time users up.

Key Takeaways

• —Ipamorelin is a selective ghrelin receptor (GHSR-1a) agonist — it triggers GH release via the ghrelin pathway without affecting cortisol or prolactin (Raun et al., European Journal of Endocrinology, 1998).
• —CJC-1295 is a growth hormone-releasing hormone (GHRH) analog — it binds GHRH receptors to stimulate the somatotropic axis via an orthogonal mechanism (Teichman et al., JCEM, 2006).
• —Combining both produces additive-to-synergistic GH pulses in healthy volunteers; neither replaces the other.
• —CJC-1295 exists in two forms: "DAC" (with drug affinity complex — 6–8 day half-life) and "non-DAC" / Mod GRF 1-29 (~30-minute half-life). They are not interchangeable.
• —Ipamorelin dosing is typically 200–300 mcg once or twice daily; CJC-1295 DAC is weekly; non-DAC CJC-1295 mirrors ipamorelin (daily, often pre-bed).

The Core Distinction: Two Receptors, One Outcome

Growth hormone release from the pituitary is controlled by two stimulatory inputs and one inhibitory input. GHRH (growth hormone-releasing hormone) from the hypothalamus binds the GHRH receptor on pituitary somatotrophs to stimulate GH release. Ghrelin — an appetite-linked peptide from the stomach — binds GHSR-1a on the same somatotrophs and drives GH release through a parallel pathway. Somatostatin suppresses both.

The two stimulatory pathways converge on GH release but operate through different receptors and different intracellular cascades. That's the mechanistic argument for combining them: if you amplify both inputs, you get a larger GH pulse than either alone produces. Published human data supports this — in healthy male volunteers, co-administration of a GHRH analog with a ghrelin-receptor agonist produced GH peaks ~3–5x higher than either alone (Hataya et al., JCEM, 2001).

What Ipamorelin Does Alone

Ipamorelin is a pentapeptide (H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂) designed as a selective agonist of GHSR-1a, the ghrelin receptor. Its selectivity is its defining property. Earlier ghrelin-mimetics (GHRP-2, GHRP-6) also triggered cortisol and prolactin release because they hit related receptors. Ipamorelin was engineered to hit GHSR-1a with high affinity while avoiding cortisol, ACTH, and prolactin activation (Raun et al., 1998).

Clean selectivity matters because the whole purpose of a ghrelin-mimetic for GH purposes is to get GH release without the stress-axis side effects that plague broader secretagogues. The trade-off is effect size: ipamorelin produces a smaller GH pulse per dose than GHRP-2, but without the cortisol spike, ACTH elevation, or hunger increase.

Half-life: ~2 hours (human subcutaneous). Typical research dose: 200–300 mcg subcutaneous, 1–3 times daily. Common use pattern: pre-bed dose to align with natural overnight GH pulse.

What CJC-1295 Does Alone

CJC-1295 is a 30-amino-acid analog of GHRH (residues 1–29 of endogenous GHRH, with four amino acid substitutions to resist enzymatic degradation). It binds the GHRH receptor on pituitary somatotrophs to trigger GH release.

The critical detail is the existence of two versions with very different pharmacokinetics.

CJC-1295 DAC (with Drug Affinity Complex) contains a maleimide group that covalently binds to serum albumin after injection. This dramatically extends half-life — published data shows ~6–8 days (Teichman et al., JCEM, 2006). In clinical trials, weekly dosing of CJC-1295 DAC at 60–250 mcg/kg produced sustained GHRH-receptor activation and elevated IGF-1 for the full inter-dose interval.

CJC-1295 without DAC — also sold as Mod GRF 1-29 — has the same amino acid substitutions but lacks the albumin-binding group. Half-life drops to ~30 minutes. This version mirrors ipamorelin's dosing rhythm: it's designed for daily pulsatile administration, not weekly.

The two versions are not clinically interchangeable. DAC produces continuous GHRH signalling; non-DAC produces pulsatile GHRH signalling. These have different physiological effects, and the "CJC-1295 + ipamorelin" protocol that appears in most peptide references specifically uses non-DAC CJC-1295. Mixing DAC with ipamorelin is a different protocol with different trade-offs.

Head-to-Head Comparison

Ipamorelin alone gives you a clean ghrelin-pathway GH pulse without stress-axis activation. Effect size is modest but side effect profile is clean.

CJC-1295 non-DAC alone gives you a clean GHRH-pathway GH pulse that preserves natural pulsatility. Rarely used alone in practice because pairing with ipamorelin is mechanistically superior.

CJC-1295 DAC alone gives you sustained GHRH signalling and elevated IGF-1. Pulsatility is lost. This matters because chronic GHRH-receptor activation can eventually desensitise the pituitary response, whereas pulsatile signalling maintains responsiveness.

Why the Combination Dominates Protocols

Ipamorelin + CJC-1295 (non-DAC) is one of the most-used pairings in practitioner peptide protocols, and the mechanistic argument for it is clean:

1. —Independent receptors. Ghrelin-receptor activation and GHRH-receptor activation converge on GH release but come from different intracellular cascades. Stacking both inputs sums rather than competes.
2. —Preserved pulsatility. Both peptides have short half-lives, so dosing doesn't desensitise the pituitary response. Multiple pulses per day remain effective.
3. —No stress-axis activation. Neither peptide triggers cortisol, ACTH, or prolactin. This is a pure GH-axis stimulus.
4. —Sum greater than parts. Published GHRH + ghrelin-mimetic co-administration data shows 3–5x GH peaks over either alone.

A typical protocol pairs 200 mcg ipamorelin + 100 mcg CJC-1295 (non-DAC) subcutaneous, once to three times daily. The pre-bed dose is almost universally included because overnight is when natural GH pulse is largest, and compounding both with the endogenous pulse magnifies effect.

CJC-1295 DAC stacked with ipamorelin is a different protocol — weekly DAC injection + daily ipamorelin — and is less common because continuous GHRH signalling partially undermines ipamorelin's pulsatile advantage.

What the Human Evidence Actually Shows

Ipamorelin had pharmaceutical industry development through Novo Nordisk as a functional GI motility agent (not a GH therapy). Phase 2 human trials completed for postoperative ileus showed good tolerability and some efficacy before development was discontinued — unrelated to safety (Beck et al., Aliment Pharmacol Ther, 2014). GH and IGF-1 elevation data from these trials exist but the drug was never developed for GH indications.

CJC-1295 DAC was developed by ConjuChem and completed Phase 2 trials in GH-deficient adults and HIV-associated lipodystrophy. Weekly dosing sustained IGF-1 elevation for the full inter-dose interval at well-tolerated doses. Development was discontinued for commercial reasons, not safety concerns.

Neither peptide has FDA approval. Neither has published human data for the anti-aging or body recomposition indications they are commonly marketed for in the research-peptide space.

Safety Profile

Both peptides share a generally favourable preclinical safety record. Common practitioner-reported effects:

• —Injection site reactions (mild erythema, tenderness) — common with any subcutaneous peptide
• —Transient headaches — more common with CJC-1295, typically resolve within first week
• —Water retention / facial puffiness — proportional to GH/IGF-1 elevation, more pronounced at higher doses or with DAC forms
• —Elevated fasting insulin — GH elevates insulin resistance transiently; clinically relevant at high doses or in insulin-sensitive individuals

Both are banned by WADA. Both are not FDA-approved. Neither has been formally studied in pregnancy, lactation, or pediatric populations.

Choosing Between (or Combining) Them

• —Single-compound starting point: ipamorelin alone at 200–300 mcg pre-bed for 4 weeks establishes baseline tolerability and effect.
• —Full mechanism stack (most common): ipamorelin 200 mcg + CJC-1295 non-DAC 100 mcg, subcutaneous, 1–2x daily, 8–12 week cycles.
• —Weekly compliance preference: CJC-1295 DAC at 1–2 mg weekly, with or without concurrent daily ipamorelin.
• —Minimise cortisol impact: ipamorelin is preferred over GHRP-2 or GHRP-6 (which are also ghrelin-mimetics but less selective).

The existing ipamorelin + CJC-1295 stack guide covers full protocol detail. For individual profile data, see the ipamorelin research profile and the CJC-1295 entry in the library.

Frequently Asked Questions

Is CJC-1295 better than ipamorelin alone?

They're not directly comparable — they hit different receptors. CJC-1295 (either form) alone gives GHRH-pathway GH release. Ipamorelin alone gives ghrelin-pathway GH release. Neither is "better"; they're complementary, which is why most protocols use both.

What's the difference between CJC-1295 DAC and Mod GRF 1-29?

Mod GRF 1-29 is the same peptide as CJC-1295 without the drug-affinity-complex (albumin-binding) group. It has a ~30-minute half-life vs DAC's 6–8 days. For daily pulsatile dosing with ipamorelin, non-DAC / Mod GRF is used. DAC is used for weekly sustained signalling.

Do you have to stack them or can you run each alone?

You can run either alone. Ipamorelin alone is a reasonable starting protocol. CJC-1295 alone (in practice) is rare because the mechanistic rationale for adding ipamorelin is strong and side effect profile of the combination isn't meaningfully worse than monotherapy.

When is CJC-1295 DAC preferred over non-DAC?

When weekly injection compliance matters more than preserved pulsatility — for example, clinical research contexts where dosing frequency is a trial-design constraint, or long protocols where daily injection adherence would drop. For most practitioner protocols aimed at maximising GH pulse without desensitisation, non-DAC is preferred.

Do these peptides raise cortisol?

No. This was the specific design goal for ipamorelin and it distinguishes it from earlier ghrelin-mimetics (GHRP-6, GHRP-2). CJC-1295 is a GHRH analog and doesn't hit the adrenal axis at all.

Bottom Line

Ipamorelin and CJC-1295 hit different receptors and their effects add together mechanistically — that's why almost no serious protocol uses one without the other. The real choice is CJC-1295 DAC vs non-DAC, which is a pulsatility vs convenience decision, not a mechanism decision. If you're new to either, start with ipamorelin alone for a short cycle to establish tolerability; add non-DAC CJC-1295 next for the full combination.

This article is for research and informational purposes only. Ipamorelin and CJC-1295 are not FDA-approved for human clinical use. Banned by WADA in competitive sport.